Mohanjit Brar, MD
Interventional Cardiology · Edgewood, KYNPI 1386665040
Payments from drug & device makers
Across 544 payments — averaging $396.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cathworks, Inc.$95K
- Johnson & Johnson$47K
- Medtronic$28K
- Magenta Medical Inc$23K
- Abbott$6K
- Abiomed$3K
- plus $12K from 32 others
What the payments were for
- Consulting fees$4,0005%
- Speaking & faculty fees$44,49559%
- Travel & lodging$7,0289%
- Food & beverage$20,22727%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cathworks, Inc. | 11 | $94,638 |
| Johnson & Johnson | 186 | $47,317 |
| Medtronic(2 entities) | 31 | $28,398 |
| Magenta Medical Inc | 5 | $23,423 |
| Abbott | 55 | $6,140 |
| Abiomed | 33 | $3,419 |
| Edwards Lifesciences | 63 | $2,994 |
| Inari Medical, Inc. | 15 | $2,300 |
| Boston Scientific | 39 | $2,272 |
| Cardiovascular Systems Inc. | 8 | $1,445 |
| Intuitive Surgical | 3 | $394 |
| Penumbra, Inc. | 3 | $350 |
| Novartis | 25 | $334 |
| Stryker | 3 | $304 |
| Angiodynamics, Inc. | 3 | $254 |
| AstraZeneca | 6 | $243 |
| Amgen | 6 | $199 |
| Pfizer | 12 | $174 |
| Boehringer Ingelheim | 4 | $173 |
| Impulse Dynamics (USA) Inc. | 1 | $171 |
| Shockwave Medical, Inc | 1 | $147 |
| Getinge USA Sales, LLC | 3 | $141 |
| Acist Medical Systems, Inc. | 3 | $85 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Reflow Medical Inc | 1 | $53 |
| Biosense Webster, Inc. | 2 | $49 |
| Kestra Medical Technology Services, Inc. | 2 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Bayer | 2 | $33 |
| Chiesi USA, Inc. | 2 | $26 |
| Cardiva Medical, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $18 |
| Vifor Pharma, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$45,545
- FLOWTRIEVER CATHETER, S$2,257
- CT THROMBECTOMY SYSTEM KIT$2,257
- Impella$2,083
- TRICLIP$1,185
- Peripheral Orbital Atherectomy System$1,097
- Mitra Clip system$1,053
- COREVALVE EVOLUT R$1,022
- SUPERA$974
- Edwards SAPIEN 3 Transcatheter Heart Valve$609
- CoreValve Evolut$473
- Da Vinci Surgical System$388
- SAPIEN 3 Ultra RESILIA$375
- LOTUS EDGE$366
- GENERAL - STENTS$364
- OPTIMIZER$343
- MitraClip System$266
- AVVIGO Guidance System$252
- Watchman$229
- Diamondback Coronary$226
How this compares
$215,782 in reported general payments places this provider in the 90th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 289 | $325,714 |
| EliquisApixaban | 273 | $267,882 |
| Repatha SureclickEvolocumab | 78 | $58,725 |
| EntrestoSacubitril/Valsartan | 30 | $40,839 |
| FarxigaDapagliflozin Propanediol | 27 | $35,770 |
| Praluent PenAlirocumab | 25 | $24,805 |
| BrilintaTicagrelor | 16 | $14,085 |
| VascepaIcosapent Ethyl | 23 | $13,916 |
| Metoprolol Succinate | 517 | $6,770 |
| Ranolazine ErRanolazine | 75 | $6,244 |
| Bisoprolol Fumarate | 159 | $3,111 |
| Torsemide | 180 | $2,710 |
| Atorvastatin Calcium | 296 | $2,412 |
| Amiodarone Hcl | 42 | $2,117 |
| Losartan Potassium | 207 | $1,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $47,317 | $325,714289 claims |
| PfizerEliquis | $174 | $267,882273 claims |
| AstraZenecaFarxiga, Brilinta | $243 | $49,85643 claims |
| NovartisEntresto | $334 | $40,83930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Edgewood
- Amit SrivastavaEdgewood$736K
- Abiodun IsholaEdgewood$52K
- Damodhar SureshEdgewood$30K
- Saeb KhouryEdgewood$17K
- Thomas TuLouisville$1.4M
- Avichai EresLexington$616K
- Naresh SolankhiLouisville$545K
- Sreedevi GondiLouisville$535K
- Steve LinLexington$372K
- Daniel StewartLouisville$290K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.